Browse the evidence

Metabolic adaptation in energy expenditure (adaptive thermogenesis) was unrelated to the energy cost of weight and fat mass gains.

Weight gain responses may not be influenced by changes in metabolic rate during overfeeding.

Semaglutide did not offer significant advantages in lowering HbA1C levels compared to other hypoglycemic treatments.

Practitioners should be cautious in expecting significant HbA1C improvements with Semaglutide.

Consensus recommendations for safe practices in bariatric and metabolic surgery tourism (BMT) were established by healthcare professionals and patient representatives across Europe.

Healthcare providers should adhere to the established consensus recommendations for BMT.

Further evaluation is required regarding outcomes following bariatric and metabolic surgery tourism.

Ongoing research is essential to assess the effectiveness and safety of BMT practices.

Injectable pharmacotherapies are effective strategies to manage obesity by targeting metabolic pathways.

Practitioners can consider injectable pharmacotherapies as a viable option for obesity management.

Significant weight loss can lead to aesthetic challenges such as skin laxity.

Practitioners should be aware of potential aesthetic issues in patients after significant weight loss.

GLP-1RA use was associated with increased fracture risk in nondiabetic patients who were overweight or obese (3.05% vs. 2.61%, OR 1.19, CI [1.09 to 1.31]).

Practitioners should consider the increased fracture risk when prescribing GLP-1RAs to overweight or obese nondiabetic patients.

In patients with a BMI ≥40, fracture risk was significantly increased with GLP-1RA use (3.15% vs. 1.91%, OR 1.26, CI [1.04 to 1.52]).

Higher BMI patients may require closer monitoring for fracture risk when prescribed GLP-1RAs.

Patients older than 67 years showed a significant increase in fracture risk with GLP-1RA use, particularly those aged 68 to 77 years (5.61% vs. 3.65%, OR 2.25, CI [1.62 to 3.13]) and 78 to 88 years (9.28% vs. 5.10%, OR 4.99, CI [2.68 to 9.26]).

Older patients may be at higher risk for fractures when prescribed GLP-1RAs and should be monitored accordingly.

If access to GLP-1RAs was restricted to people with severe obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 7476.

Restricting GLP-1RA access to those with severe obesity can still lead to significant cancer case reductions.

Patients receiving semaglutide within 10 days of surgery have a significantly increased risk of residual gastric content compared to a control sample (40% vs. 3%).

Clinicians should be cautious when managing patients on semaglutide in the peri-operative setting due to increased aspiration risk.

Increased residual gastric content was observed regardless of whether patients held semaglutide for 1–7 or 8–10 days pre-operatively.

The duration of holding semaglutide before surgery may not mitigate the risk of residual gastric content.

Increased residual gastric content can persist up to 10 days after stopping subcutaneous semaglutide.

Clinicians may need to consider longer pre-operative interruption intervals for patients on semaglutide to reduce aspiration risk.

Adverse side effects from GLP-1 receptor agonists are mostly gastrointestinal but may also include loss of muscle and bone mass.

Monitor for gastrointestinal side effects and potential muscle and bone mass loss in patients using GLP-1 receptor agonists.

The intervention subjects lost more weight than the control subjects (-4.1 kg vs -2.1 kg), but the difference was not statistically significant (p = 0.22).

Practitioners may consider remote dietitian support for weight loss in patients before joint surgery.

The intervention subjects had higher odds of achieving a BMI of <40 kg/m 2 (odds ratio = 1.9), but this was not statistically significant (p = 0.44).

Practitioners may find that remote interventions can help some patients achieve a healthier BMI before surgery.

Mitochondrial uncoupling promotes energy dissipation and may serve as a strategy for obesity treatment.

Practitioners may consider mitochondrial uncoupling as a potential target for obesity interventions.

Observational data show a reduction in all-cause mortality and cancer risk in patients who have undergone bariatric surgery.

Bariatric surgery may significantly improve long-term health outcomes and reduce mortality risk.

Obesity is a chronic multifactorial disease.

Understanding obesity as a multifactorial disease is crucial for effective treatment.

Sustained significant weight loss through lifestyle changes is difficult for people with obesity in the long term.

Practitioners should be aware of the challenges faced by patients in achieving long-term weight loss.

HEC-CG115 led to more weight loss than semaglutide in diet-induced obese model mice.

HEC-CG115 may be a more effective option for weight loss in obese patients compared to semaglutide.

Performing additional sets of resistance exercise does not inherently result in greater increases in muscle size compared to lower volumes.

Practitioners should not assume that increasing the number of sets will always lead to greater muscle growth.

There has been limited success in curbing the incidence of T2D despite lifestyle modification being standard care.

Practitioners should recognize the barriers to effective lifestyle interventions.

Gastric bypass patients had an 85% lower risk of developing type 2 diabetes compared to non-operated patients with obesity during the first six years of follow-up.

Gastric bypass surgery significantly reduces the risk of type 2 diabetes in obese patients, especially in the first six years post-surgery.